Silicon-zinc-containing glycerohydrogel, possessing wound healing, regenerative and antibacterial activity

FIELD: chemistry.

SUBSTANCE: claimed is a silicon-zinc-containing glycerohydrogel, possessing a wound healing, regenerative and antibacterial activity, a composition of which corresponds to formula kSi(C3H7O3)4·ZnC3H6O3·xC3H8O3·yH2O, where 1≤k≤4, 7≤x≤26, 20≤y≤100, obtained by interaction of tetraglycerolate of silicon in excess of glycerol Si(C3H7O3)4·xC3H8O3, where 0,5≤x≤10, monoglycerolate of zinc in abundance of glycerol ZnC3H6O3·6C3H8O3 and water in molar ratio Si(C3H7O3)4:ZnC3H6O3:C3H8O3:H2O equal to (1÷4):1:(7÷26):(20÷100) at a temperature of 20-40°C and intensive mixing.

EFFECT: claimed silicon-zinc-containing glycerohydrogel possesses the wound healing, regenerative and antibacterial activity, is simple to obtain and convenient in application.

1 tbl, 6 ex

 

The invention relates to pharmaceutical chemistry and medicine, in particular, to a new biologically active chemical substance - creditinterest glycerokinase, which may find application as a drug with wound healing, regenerating and anti-bacterial activity.

Known monoglycerol zinc ZnC3H6O3possessing pharmacological activity, which are usually used topically to treat skin diseases. The so-described wound healing, and regenerative activity monoglycerol zinc when used in powder form in a cream/ointment in the treatment of burns, ulcers, eczema, herpes (Appl. WO 94/02133, IPC A61K 31/45, 1994, Appl. US 20060173073, IPC A61K 31/315, 2006). In addition, monoglycerol zinc exhibits antibacterial activity against several gram-positive and gram-negative microorganisms (Pat. US 4876278, IPC A61K 31/045, 1989).

A disadvantage of the known tools is the inability of its use in a convenient gel form, because there is no information about the possibility of the formation of hydrogels from monoglycerol zinc.

Known tetrapyrrolic silicon synthesized in excess of glycerol, the composition of which corresponds to the formula Si(C3H7About3)4·CH3H8About3where 0.5≤x≤10, and glycerokinase is as its basis, has anti-inflammatory, wound healing, regenerating effect (U.S. Pat. EN 2255939, C07F 7/04, A61K 47/30, 2005). Glycerokinase was obtained by adding water containing an electrolyte (e.g., HCl)to tetrapyrrolic silicon in excess of glycerine at a temperature of 80°C.

However, the known glycerokinase does not possess antibacterial activity against gram-positive and gram-negative microorganisms.

Thus, the authors had the task to expand the Arsenal of drugs to get a new tool with wound healing, regenerating and anti-bacterial activity, which can be used in gel form. The tool should be non-toxic, easy to obtain and well reproducible in the way of getting when using the available raw materials, stable during storage, convenient for practical use.

The problem is solved by obtaining creditinsurance of glycomolecules with wound healing, regenerating and anti-bacterial activity, the composition of which corresponds to the formula kSi(C3H7About3)4·ZnC3H6O3·CH3H8About3·yH2O, where 1≤k≤4, 7≤x≤26, 20≤y≤100, obtained by the interaction tetrapyrrole silicon in excess of glycerol Si(C3H7the 3)4·CH3H8About3where 0.5≤x≤10, monoglycerol zinc in excess of glycerol ZnC3H6O3·6C3H8About3and water at a molar ratio of Si(C3H7About3)4:ZnC3H6O3:C3H8About3:H2About equal(1÷4):1:(7÷26):(20÷100) at a temperature of 20-40°C and vigorous stirring.

Currently in the patent and scientific literature is not known biologically active creditinterest glycerokinase with wound healing, regenerating and anti-bacterial activity, non-toxic, easy to use, which would be obtained by the proposed method and contained the claimed components at specified intervals.

Creditinterest glycerokinase whose composition corresponds to the formula kSi(C3H7About3)4·ZnC3H6O3·CH3H8About3·yH2O, where 1≤k≤4, 7≤x≤26, 20≤y≤100, can be obtained as follows. Tetrapyrrolic silicon in excess of glycerol Si(C3H7About3)4·CH3H8About3where 0.5≤x≤10, obtained in the form of a transparent viscous liquid (U.S. Pat. EN 2255939, C07F 7/04, A61K 47/30, 2005), and monoglycerol zinc in excess of glycerol ZnC3H6O3·6C3H8About3obtained in the form of a colloidal suspension (Pat. US 4544761, MP is A61L 15/20, SS 31/28, 1985), mixed at a temperature of 20-40°C, followed by addition of water at a molar ratio of Si(C3H7O3)4:ZnC3H6O3:C3H8About3:H2About equal(1÷4):1:(7÷26):(20÷100) and stirring up the losses in the system fluidity with the formation of a homogeneous gel white. The product is characterized by the data of elemental analysis and IR spectroscopy.

Education creditinsurance of glycomolecules corresponds to the Sol-gel process including chemical reaction of hydrolysis and condensation of the original substances (precursors), are closely associated with the physical phenomena of coagulation and adsorption. The resulting glycerokinase contains in its structure at the same time chemically bonded to the silicon atoms and zinc in biologically active form.

The authors have conducted experimental studies on the choice of the molar ratio tetrapyrrole silicon, monoglycerol zinc, glycerin and water to obtain the optimal conditions of glycerokinase, stable to syneresis. So, the content of tetrapyrrole silicon and monoglycerol zinc should correspond to an optimum ratio of silicon atoms and zinc, which allows to obtain a synergistic effect in terms of pharmacological activity of glycerokinase, resistance to the phenomenon of syneresis, and is more acceptable consistency for practical application. So, when the molar content tetrapyrrole silicon less than the proposed (k<1) education of glycomolecules does not occur. In the case of content tetrapyrrole silicon offer more (k>4) the resulting product does not have a pronounced antibacterial activity. When the molar content of glycerin and water over offer (x>26 & y>100) glycerokinase undergoes syneresis, in addition, due to an excess of glycerol becomes "greasy" texture; content of glycerin and water less than the proposed (x<7 and y<20) is formed of a hard, brittle, cracking during storage and Molodoy in the application of the product.

The following examples describe the method of preparation and composition creditinsurance of glycerokinase, determination of its antibacterial activity (in vitro), acute toxicity, and the study of wound healing, and regenerative activity (for example, experimental animals).

Example 1. Getting creditinsurance of glycomolecules 2Si(C3H7About3)4·ZnC3H6O3·7C3H8About3·20N2O.

45,08 g (0,103 mol) tetrapyrrole silicon in excess of glycerol Si(C3H7About3)4·0,5S3H8About3and 36,39 g (0,051 mol) monoglycerol zinc in excess of glycerol ZnC3H6O3·6C3H About3mixed at a temperature of 20°C to obtain a homogeneous mass. Then at 40°C and intensive stirring holds 18.52 g (1,028 mol) of water (molar ratio of the components Si(C3H7About3)4:ZnC3H6O3:C3H8About3:H2O=2:1:7:20) and continue to stir until a homogeneous gel is white in color.

The composition of the product corresponds to the formula 2Si(C3H7About3)4·ZnC3H6O3·7C3H8About3·20N2O.

Found (%): 29,57; N 8,11; Si 2,95; Zn 3,30. C48H158O68Si2Zn.

Calculated (%): 29,64; N 8,19; Si 2,89; Zn 3,36.

IR spectrum, ν/cm-1: 3282, 1647 (HE); 2933, 2880 (C-H); 1107, 1036, 989 (Si-O-C); 1107 (C-O-C), 647 (Zn-O).

Example 2. Getting creditinsurance of glycomolecules 2Si(C3H7About3)4·ZnC3H6O3·7C3H8About3·100N2O.

25,89 g (0,059 mol) tetrapyrrole silicon in excess of glycerol Si(C3H7About3)4·0,5S3H8About3and 20,90 g (0,029 mol) monoglycerol zinc in excess of glycerol ZnC3H6O3·6C3H8O3mixed at a temperature of 20°C to obtain a homogeneous mass. Then at 40°C and intensive stirring, 53,20 g (2,953 mol) of water (molar ratio of the components Si(C3 H7About3)4:ZnC3H6O3:C3H8About3:H2O=2:1:7:100) and continue to stir until a homogeneous gel is white in color.

The composition of the product corresponds to the formula 2Si(C3H7About3)4·ZnC3H6O3S3H8About3·100N2O.

Found (%): 16,94; N 9,42; Si 1,72; Zn 1,87. C48H318O148Si2Zn.

Calculated (%): 17,02; N For 9.47; Si 1,66; Zn 1,93.

IR spectrum, ν/cm-1: 3278, 1643 (HE); 2945, 2885 (C-H); 1115, 1037, 993 (Si-O-C); 1115 (C-O-C), 650 (Zn-O).

Example 3. Getting creditinsurance of glycomolecules 2Si(C3H7About3)4·ZnC3H6O3·26C3H8About3·20N2O.

71,09 g (0,054 mol) tetrapyrrole silicon in excess of glycerol Si(C3H7About3)4·10C3H8About3and 19,16 g (0,027 mol) monoglycerol zinc in excess of glycerol ZnC3H6O3·6C3H8O3mixed at a temperature of 20°C to obtain a homogeneous mass. Then at 40°C and intensive stirring of 9.75 g (0,541 mol) of water (molar ratio of the components Si(C3H7About3)4:ZnC3H6O3:C3H8O3:H2O=2:1:26:20) and continue to stir until a homogeneous gel is white in color.

The composition of the obtained product which corresponds to the formula 2Si(C 3H7About3)4·ZnC3H6O3·26C3H8About3·20N2O.

Found (%): 33,92; N At 8.36; Si 1,60; Zn 1,67. C105H310O125Si2Zn.

Calculated (%): 34,13; N 8,46; Si 1,52; Zn 1.77 In.

IR spectrum, ν/cm-1: 3285, 1652 (HE); 2934, 2880 (C-H); 1107, 1031, 990 (Si-O-C); 1107 (C-O-C), 643 (Zn-O).

Example 4. Getting creditinsurance of glycomolecules 2Si(C3H7O3)4·ZnC3H6O3·26C3H8About3·100N2O.

51,13 g (0,039 mol) tetrapyrrole silicon in excess of glycerol Si(C3H7About3)4·10C3H8About3and 13,78 g (0.019 mol) monoglycerol zinc in excess of glycerol ZnC3H6O3·6C3H8O3mixed at a temperature of 20°C to obtain a homogeneous mass. Then at 40°C and intensive stirring 35,07 g (1,947 mol) of water (molar ratio of the components Si(C3H7O3)4:ZnC3H6O3:C3H8About3:H2O=2:1:26:100) and continue to stir until a homogeneous gel is white in color.

The composition of the product corresponds to the formula 2Si(C3H7About3)4·ZnC3H6O2·ZnC3H8O3·100N2O.

Found (%): 24,49; N 9,15; Si 1,11; Zn 1,17. C105H470O205Si2Zn.

Calculated (%): From RUB 24.55; N. 9,2; Si 1,09; Zn 1,27.

IR spectrum, ν/cm-1: 3271, 1646 (HE); 2940, 2883 (C-H); 1109, 1036, 992 (Si-O-C); 1109 (C-O-C), 650 (Zn-O).

Example 5. Getting creditinsurance of glycomolecules Si(C3H7About3)4·ZnC3H6O3·12C3H8About3·N2O.

35,50 g (of 0.038 mol) tetrapyrrole silicon in excess of glycerol Si(C3H7About3)4·6C3H8About3and 26,60 g (of 0.038 mol) monoglycerol zinc in excess of glycerol ZnC3H6O3·6C3H8O3mixed at a temperature of 20°C to obtain a homogeneous mass. Then at 20°C and intensive stirring 37,90 g (2,104 mol) of water (molar ratio of the components Si(C3H7About3)4:ZnC3H6O3:C3H8About3:H2O=1:1:12:56) and continue to stir until a homogeneous gel is white in color.

The composition of the product corresponds to the formula Si(C3H7About3)4·ZnC3H6O3·12C3H8About3·N2O.

Found (%): 22,94; N 9,10; Si 1,12; Zn Is 2.37. C51H242O107SiZn.

Calculated (%): 23,01; N 9,16; Si 1,06; Zn 2,46.

IR spectrum, ν/cm-1: 3292, 1645 (HE); 2932, 2881 (C-H); 1110, 1038, 992 (Si-O-C); 1110 (C-O-C), 647 (Zn-O).

Example 6. Getting creditinsurance of glycomolecules 4Si(C3H7About3)4·ZnC3H O3·18C3H8About3·N2O.

59,92 g (0,090 mol) tetrapyrrole silicon in excess of glycerol Si(C3H7About3)4·3C3H8About3and 15,86 g (0,022 mol) monoglycerol zinc in excess of glycerol ZnC3H6O3·6C3H8O3mixed at a temperature of 20°C to obtain a homogeneous mass. Then at 40°C and intensive stirring 24,21 g (1,344 mol) of water (molar ratio of the components Si(C3H7About3)4:ZnC3H6O3:C3H8About3:H2O=4:1:18:60) and continue to stir until a homogeneous gel is white in color.

The composition of the product corresponds to the formula 4Si(C3H7About3)4·ZnC3H6O3·18C3H8About3·N2O.

Found (%): As Opposed To 28.18 Per; N 8,55; Si 2,58; Zn 1,36. C105H382O165Zn.

Calculated (%): 28,25; N 8,63; Si 2,52; Zn 1,46.

IR spectrum, ν/cm-1: 3294, 1646 (HE); 2932, 2880 (C-H); 1110, 1037, 990 (Si-O-C); 1111 (C-O-C), 650 (Zn-O).

Microbiological testing of the proposed drug in vitro is made in the Center for military-technical problems of biological protection research Institute of Microbiology of the Ministry of defense (Ekaterinburg).

Evaluation of antibacterial properties creditinsurance of glycomolecules whose composition corresponds to the formula Si(C3H7About3 )4·ZnC3H6O3·12C3H8About3·N2(Example 5), in respect of the following strains tested cultures of microorganisms: Staphylococcus aureus 906, Staphylococcus epidermidis 14990, Streptococcus pyogenes ATCC 19615, Pseudomonas aeruginosa 9027, Escherichia coli 25922.

Test cultures were grown at 37°C for 18-24 hours on a beveled mesopatamia agar.

To study the antibacterial properties of glycomolecules used the method of diffusion in agar. In sterile Petri dishes (plastic disposable) was poured into nutrient agar medium (containing amine nitrogen 30 mg% and pH 7.0 to 7.2). Previously melted and cooled to 45-48°C environment has made the appropriate test culture at a concentration of 1×107microbial cells (optical standard turbidity) 1 cm environment. After hardening and drying of the nutrient medium for 60 min on its surface superimposed rings, stainless steel rings with an inner diameter of ring (6,0±0,1) mm and height (2,5±0,1) mm rings were placed hanging glycerokinase, vaseline and liniment of streptocide 5%soluble (as a control). Weight hanging, placed in a ring, was ~ 50 mg. largest zone of inhibition of growth around the ring (diameter growth) after 20-hour incubation at a temperature of (36,0±1,0°C was judged on the absence or presence and degree of expression the activity of antibacterial action proposed glycerokinase. The results are presented in the table.

Table
The size of zones of inhibition of growth of the test cultures to declare creditinsurance of glycomolecules Si(C3H7About3)4·ZnC3H6O3·12C3H8About3·N2About
The test-cultureThe largest zone of inhibition of growth, mm
S.aureus 90615,0±1,1
S.epidermidis 1499018,0±0,9
Of these bacteria to antibiotics ATCC 1961514,0±1,1
P.aeruginosa 9027>25,0
E.coli 25922>28,0
Control (vaseline)the zone of inhibition no
Control (liniment of streptocide)18,0-22,5

As can be seen from the table, creditinterest glycerokinase has moderate antibacterial activity, covering aerobic bacterial forms of gram-positive and gram-negative microorganisms. Among the studied strains is more sensitive is the test culture gram-negative bacteria E. coli and P. aeruginosa.

Toxicological studies of the proposed drug in vivo

Research performed at the Department of pharmacology of the Ural state medical Academy Ministry of health of the Russian Federation (Yekaterinburg).

The study of the acute toxicity creditinsurance of glycomolecules whose composition corresponds to the formula Si(C3H7About3)4·ZnC3H6O3·12C3H8About3·N2(Example 5), conducted according to the guidelines for preclinical testing of drugs", edited by A.N. Mironov (part 1. M: Neck and, 2012, 944 S.) on white outbred mice weighing 30-40 g Experimental animals were kept in a vivarium at a temperature of 18-20°C under natural light cycle on a standard diet with free access to food and water.

The study gel was injected into the stomach through a tube and intraperitoneally once in the form of a 50% aqueous slurry in the amount of 0.5-1.0 ml (the volume of the stomach).

After the introduction of glycomolecules hourly observed the behavior of the animals during the first day, and in the next 13 days daily. During the experiment were recorded depending on the dose of General locomotor activity of animals, neuromuscular excitability, reflexes (pain, corneal), autonomic response (salivation, diuresis,defecation).

Found that intragastric and intraperitoneal application of the proposed glycerokinase experimental animals remained alive, and signs of intoxication were not detected during the entire period of observation. All monitored parameters in animals of experimental groups did not differ significantly from those of control groups.

Thus, the test substance (according to GOST 12.1.007-76) refers to low-toxic compounds (IV class of danger).

Studies of wound healing, and regenerative activity of the proposed drug in vivo

The study was performed on the model of thermal injury of the mucous membrane of the lower lip of the rat population Wistar weighing 280-330 g Rats were divided into 3 groups of 10 animals each. Rats 1 (experimental) and 2 (control) groups for broadcasting Rausch-anesthesia was applied thermal burn using heated to 100°With a metal spatula with 20-second contact with the mucous membrane of the lower lip; group 3 remained intact, the control treatment was not received.

The treatment of animals of the experimental group was started a day after creating a thermal burn and conducted in an open way, causing a thin layer creditinsurance of glycomolecules whose composition corresponds to the formula Si(C3H7About3)4·ZnC3H6O3·12C H8About3·N2(Example 5) (- 0.1 g), directly to the lesions once daily in the morning hours until complete wound healing.

On injured areas of the mucosa due to the treatment with the inventive tool among all the experimental rats epithelialization occurred ~ 5 days with a trend towards more rapid reduction of hyperemia and edema of the mucosa. In the control group, complete wound healing was observed ~ on the 7th day.

Dynamics of change in weight of rats experimental and control groups indicate that reduction of body weight on average ~5% during the experiment. In intact animals, in contrast, was observed weight gain on average ~5%. The variation of this indicator is explained by the difficulty of eating animals in the severe pain of the lower lip area.

Before applying the burns and the treatment investigated the behavioral responses of animals (open field). After a course of treatment (5, 7, 10 and 14 days) the animals was General and biochemical blood tests, and morphological studies of visceral organs and mucous membranes.

Histological specimens were prepared after fixation of tissues (heart, lungs, liver, kidneys, adrenal glands, spleen, skin) 10%formalin solution and were filled with wax. Histological sections were stained with hematoxylin and eosin by van G the area. The analyzed organs without any structural changes.

The study open field was assessed by vertical and horizontal activity of animals on the following parameters: time of leaving the circle, the number of covered squares, the number of stevani, washings and zaglyadyvanie in "holes". The greatest decline in all indicators were observed in the control group; the experimental group activity was close to the original level.

Hematological and biochemical blood of animals experimental and control groups showed an inflammatory response in the first days after injury. In the process of treatment in the control group neutrophilic leukocytosis persisted up to 7 days in the test - 5 days, indicating anti-inflammatory properties of the proposed glycerokinase.

The activity of transaminases in the blood (ALT, ACT), the content of urea and hemoglobin were not significantly different in animals of the experimental and control groups, indicating the absence of the toxic effects of the proposed glycerokinase.

In the morphological studies revealed that in the control group, damage to the mucous characterized by a greater depth and degree of degenerative changes in the epithelium. On the background of the application of glycomolecules there was complete restoration of the epithelium at all during the AI fire damage with signs of proliferative activity of epithelial cells of the basal layer.

Thus, the authors proposed creditinterest glycerokinase, which is a physiologically active substance, exhibits antibacterial, wound healing and regenerating effect, improves the functional condition of the mucous membranes of the oral cavity, is a convenient form for local use, expands the Arsenal of drugs and can be recommended for use in medical practice.

Creditinterest glycerokinase with wound healing, regenerating and anti-bacterial activity, the composition of which corresponds to the formula kSi(C3H7About3)4·ZnC3H6O3·CH3H8About3·yH2O, where 1≤k≤4, 7≤x≤26, 20≤y≤100, obtained by the interaction tetrapyrrole silicon in excess of glycerol Si(C3H7O3)4·CH3H8About3where 0.5≤x≤10, monoglycerol zinc in excess of glycerol ZnC3H6O3·6C3H8About3and water in a molar ratio of Si(C3H7About3)4:ZnC3H6O3:C3H8About3:H2About equal(1÷4):1:(7÷26):(20÷100) at a temperature of 20-40°C and vigorous stirring.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to new pyrido[2,3-b]pyrazine derivatives of general formula (I), wherein radicals and symbols are specified in the patent claim. The given compounds inhibit the enzymes ERK, ERK1, ERK2, PI3K, PI3Kalpha, PI3Kbeta, PI3Kgamma, PI3Kdelta, PI3K-C2alpha, PI3K-C2beta, PI3K-Vps34p.

EFFECT: invention refers to a pharmaceutical composition to be used for preparing the drugs applicable first for treating malignant and other diseases implying the pathological cell proliferation.

10 cl, 3 tbl, 66 ex

FIELD: chemistry.

SUBSTANCE: invention relates to method of obtaining N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperasin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzolsulfonamide or its pharmaceutically acceptable salt, which includes: (a) interaction of 4,4-dimethylcyclohexanone, alkylformiate, selected from group, including methylformiate, ethylformiate, n-propylformiate, tertbutylformiate and their any combination, and first base, selected from group, including sodium hydrate, sodium tert-butoxide, potassium tert-butoxide and their any combination, with obtaining (2E)-2-(hydroxymethylene)-4,4-dimethylcyclohexanone, with separation or without separation of (2E)-2-(hydroxymethylene)-4,4-dimethylcyclohexanone; (b) interaction of (2E)-2-(hydroxymethylene)-4,4-dimethylcyclohexanone, second base, selected from group, including triethylamine, 2,6-lutidine, pyridine, imidazole, diisopropylethylamine, N-methylmorpholine, dimethylaniline and their any combination, and first reagent silyl ether protecting group, selected from group, including trimethylchlorosilane, tert-butylchlorodimethylsilane, triisopropylchlorosilane, tert-butylchlorodiphenylsilane and their any combination, with obtaining first protected (2E)-2-(hydroxymethylene)-4,4-dimethylcyclohexanone, with separation or without separation of first protected (2E)-2-(hydroxymethylene)-4,4-dimethylcyclohexanone; (c) interaction of first protected (2E)-2-(hydroxymethylene)-4,4-dimethylcyclohexanone and 4-chlorophenylmagnesium bromide with obtaining first protected (2E)-1-(4-chlorophenyl)-2-(hydroxymethylene)-4,4-dimethylcyclohexanol; with separation or without separation of first protected (2E)-1-(4-chlorophenyl)-2-(hydroxymethylene)-4,4-dimethylcyclohexanol; (d) interaction of first protected (2E)-1-(4-chlorophenyl)-2-(hydroxymethylene)-4,4-dimethylcyclohexanol and first acid, selected from group, including tetra-n-butylammoniumfluoride, trifluoroacetic acid, hydrochloric acid, sulfuric acid and any their combination, with obtaining 2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-ene-1-carbaldehyde, with separation or without separation of 2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-ene-1-carbaldehyde; (e) interaction of 2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-ene-1-carbaldehyde, ethyl 4-piperazin-1-ylbenzoate and first reducing agent, selected from group, including sodium triacetoxyborohydrode, sodium cyanoborohydride and their combinations, with separation or without separation of ethyl 4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-ene-1-yl)methyl)piperazin-1-yl)benzoate; (f) ethyl 4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-ene-1-yl)methyl)piperazin-1-yl)benzoate interaction of and aqueous solution of third base, selected from group, including sodium hydroxide, potassium hydroxide and their combinations, with separation or without separation of 4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-ene-1-yl)methyl)piperazin-1-yl)benzoic acid; and (g) interaction of 4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-ene-1-yl)methyl)piperazin-1-yl)benzoic acid, 4-(((1R)-3-morpholin-4yl-1-((phenylthio)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzolsulfonamide and first binding reagent, selected from group, including 1-ethyl-3(3-(dimethylamino)propyl)-carbodiimidhydrochloride, dicyclohexylcarbodiimide, N,N'-diisopropylcarbodiimide, 1,1'-carbonyldiimidasole and their any combination, with or without fourth base, selected from group, including 1,8-diazabicyclo(5.4.0)undec-7-ene, potassium tret-butoxide and their combinations, and with or without first auxiliary binding reagent, selected from group, including 4-dimethylaminopyridine, hydroxybenzotriazole, 1-hydroxy-7-aza-benzotriazole and any their combination, with separation or without separation of N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperasin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzolsulfonamide.

EFFECT: new method of obtaining N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperasin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzolsulfonamide, which can be applied in medicine as stimulator of apoptosis.

10 cl, 17 ex

FIELD: chemistry.

SUBSTANCE: disclosed are trialkoxysilanes of general formula I , where R1 -Si(OAlk)3 or R1=-CH=N-CH2CH2CH2Si(OAlk)3, R2=R3=-OCH2CH2O-, as silicon-containing additives for forming a monolayer on the surface of a tantalum anode made of pressed tantalum powder, as well as use of triethoxy-2-thienylsilane for the same purpose. Also disclosed is a method of making a cathode plate from a polymer electrolyte using the disclosed trialkoxysilanes and an oxide capacitor with a solid electrolyte, having a slug section of valve metals with a surface layer made of the disclosed trialkoxysilanes.

EFFECT: capacitors with improved technical and exploitational characteristics.

4 cl, 1 dwg, 3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to compounds of general formula (I), where Y is selected from -CRay=CRby- and -CHRay-CRby=CRcy-; each Ray, Rby and Rcy is independently selected from a hydrogen atom and unsubstituted C1-C12 alkyl; each R1, R2, R3, R4 and R5 is independently selected from a hydrogen atom and unsubstituted C1-C12 alkyl; R6 is selected from NR8R9 and OR10; W is selected from NR7; R7 is a hydrogen atom; R8 is a hydrogen atom; R10 is an unsubstuted C2-C12 alkenyl; R9 is a substituted C2-C12 alkenyl which is substituted in one or more positions by a halogen , OR', OCONHR' and OH, protected by a silyl ether, where R' is hydrogen; each of R11, R12, R13, R14 and R15 is independently selected from a hydrogen atom, ORa, OSiRaRbRc; and each Ra, Rb and Rc is independently selected from a hydrogen atom and unsubstituted C1-C12 alkyl. The invention also relates to a pharmaceutical composition having cytotoxic activity, which contains said compounds, use of compounds of formula (I) to prepare a medicinal agent for treating cancer and methods of producing compounds of formula (I).

EFFECT: compounds having cytotoxic activity.

23 cl, 10 dwg, 2 tbl, 10 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to application of ester compounds of benzoic acid, taken from group, which includes 1-phenylvinyl 4-methoxybenzoate; 1-(4-methoxyphenyl)-vinyl 4-tert-butyl benzoate, 1-(4-tert-butylphenyl)-vinyl 4-methoxybenzoate, 1-phenylvinyl 4-tert-butyl benzoate, 4-benzoyloxy-2-methoxybenzolsulphonic acid, 3-diethylaminophenyl benzoate and 3-(1-pyrrolidinyl) phenyl benzoate and 3-methoxy salicylate, as component for preparing composition for protection of human organism or animal or material from ultraviolet radiation, containing effective quantity at least one of claimed compounds, as component for preparing composition, which is characterised by progressive protection from UV radiation, depending on duration of sun influence and level of sun radiation, as component for preparing composition for individual hygiene, which is characterised by progressive protection from UV radiation, depending on duration of sun influence and level of sun radiation, as component for preparing industrial composition, which is characterised by progressive protection from UV radiation, depending on duration of sun influence and level of sun radiation, and as component for preparing composition, which at photo-regrouping shows quantity of obtained UV-B radiation.

EFFECT: invention also relates to composition for protecting human or animal organism or protection of material from ultraviolet radiation, contains effective quantity of at least one above mentioned ester compound of benzoic acid.

40 cl, 6 dwg, 33 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a method of producing glycidyloxyalkyl alkoxysilanes by hydrosilylation of olefin-glycide ether in the presence of a catalyst. Disclosed is a method of producing glycidyloxyalkyl alkoxysilanes of general formula (R")O-CnH2nSi(OR)3, wherein groups R independently denote a linear or branched alkyl with 1-4 carbon atoms, n is a number equal to 1, 2, 3, 4, 5, 6, 7 or 8, R'' denotes a group H2C(O)CH- or H2C(O)CHCH2-, by reacting (i) a functionalised alkene of general formula (R")OCnH2n-1 wherein R" denotes a group H2C(O)CH- or H2C(O)CHCH2-, and n is a number equal to 1, 2, 3, 4, 5, 6, 7 or 8, (ii) with at least one hydrogen alkoxysilane of general formula HSi(OR)3, wherein groups R independently denote a linear or branched alkyl with 1-4 carbon atoms, in the presence of (iii) at least one homogeneous catalyst selected from a group comprising Spayer catalysts and Karstedt catalysts, (iv) at least one solvent and/or at least one diluent and (v)at least one acid promoter from a group of mono- and dicarboxylic acids, wherein: components (i) alkene and (ii) hydrogen alkoxysilane, used in molar ratio of 1.8-1.0:1.0; catalyst (iii) is used in molar ratio to alkene (i) ranging from 1:1000000 to 1:25000; catalyst (iii) and promoter (v) are used in molar ratio from 1:250 to 1:25000 and the catalyst (iii) and promoter (v) are used together in a solvent and/or diluent in diluted form.

EFFECT: disclosed method enables to achieve high output of the end product compared with existing methods.

12 cl, 1 ex

FIELD: chemistry.

SUBSTANCE: invention relates to tyre and rubber industry, particularly heat stabilisers which protect rubber mixtures based on general-purpose rubber from heat ageing. The method of producing heat stabiliser involves reacting phenyl trichlorosilane with aldehyde alcohol in nitrogen medium in molar ratio 1:3.

EFFECT: method enables to obtain heat stabilisers from readily available material with improved thermomechanical properties; simple method of producing heat stabilisers due to realisation thereof in a single step and use of low temperatures.

1 dwg, 3 tbl, 9 ex

FIELD: chemistry.

SUBSTANCE: present invention relates to a method of producing silicon-furan-containing monomers which are stable over time, can be combined with epoxy resins and can modify physical-mechanical and thermomechanical properties of cured epoxide compositions. The method involves reaction of tetrachlorosilane with furfuryl alcohol in a medium of pure acetone while cooling to 0-5°C in the presence of triethylamine. Molar ratio of tetrachlorosilane:furfuryl alcohol:triethylamine is equal to 1:4:4.

EFFECT: obtaining silicon-furan-containing monomers which are stable over time, can be combined with epoxy resins and can modify physical-mechanical and thermomechanical properties of cured epoxide compositions.

1 ex

FIELD: chemistry.

SUBSTANCE: invention relates to materials for preventing or inhibiting scaling on equipment, used in industrial methods having alkaline process streams, and methods of preventing or inhibiting scaling using such materials. disclosed is a composition for reducing aluminosilicate scaling, which contains a polymer which is a product of reaction of a polyalkylene oxide polymer which is epoxide-blocked at the end and an organic compound containing amino functionality and -Si(OR")3 functionality, where R'' is selected from H, a substituted or unsubstituted C1-C20 alkyl, alkenyl, aryl or aralkyl group. Disclosed also is a method of reducing aluminosilicate scaling on equipment using the disclosed composition. The technical result is that when added to an alkaline process stream, the disclosed composition reduces or even completely prevents aluminosilicate scaling on surfaces of equipment such as walls of an evaporating apparatus and heating surfaces.

EFFECT: disclosed composition is effective at treatment concentrations which makes it cost effective.

5 cl, 11 tbl, 39 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel biologically active chemical compounds - silicon-titanium-containing polyol derivatives (glycerine, polyethylene glycol), as well as hydrogels based thereon. Disclosed are silicon-titanium-containing polyol derivatives, having transcutaneous, wound healing and regenerating activity, the composition of which in excess of polyol has the formula k(CH3)4-nSi(O-R-OH)n·Ti(O-R-OH)4·xHO-R-OH, where R=R1=CH2-CH(OH)-CH2: k=1 or 2, n=2 or 3, x=11 or 12; or R=R2=(CH2-CH2-O-)7,7CH2-CH2: k=1 or 2, n=2-4, x=2 or 3, with dynamic viscosity 1.5-90.0 Pa·s (25±0.5°C), obtained by reacting (methyl)ethoxysilane and tetrabutoxytitanium with polyol in molar ratio (1-2):1:(18-22) for R1 or (1-2):1:(8-15) for R2, respectively, while heating the reaction mass to temperature 90-140°C and holding at that temperature for not less than 6 hours with intense stirring, followed by removal of the formed alcohols. The invention also discloses hydrogels based on said polyol derivatives, containing water and a gelling additive, with the following ratio of components (wt %): silicon-titanium-containing polyol derivatives in excess of polyol - 70.730-94.970; gelling additive 0.002-0.060; water - the balance.

EFFECT: silicon-titanium-containing polyol derivatives and hydrogels based thereon are physiologically active compounds, exhibit transcutaneous and wound healing action, have significant effect on the morphofunctional condition of the skin and can be recommended for use as independent agents, as well as ointment bases of different pharmaceutical compositions with transcutaneous, wound healing and regenerating action.

2 cl, 2 dwg, 8 tbl, 6 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds in a series of chelate complexes of zinc with azomethine derivatives, namely to bis[2-(N-tozylamino)benzyliden-4'-dimethylaminophenyliminato]zinc(II) of formula I Also claimed is electroluminescent device.

EFFECT: invention makes it possible to obtain compounds, demonstrating electroluminescent properties with high brightness.

2 cl, 3 dwg, 1 tbl, 2 ex

FIELD: chemistry.

SUBSTANCE: described are 15-crown-5- and dithia-18-crown-6-containig 2-methyl-9-styryl phenanthrolines of formula: where as optical sensors on cations of calcium, barium and lead. Claimed compounds are obtained by interaction of ligand of 15-crown-5 or dithia-18-crown-6-containing 2-methyl-9-styryl phenanthroline with zinc perchlorate in acetonitrile with irradiation with red light.

EFFECT: complexes possess properties of highly efficient fluorescent sensors on cations of calcium, barium and lead, which make it possible to visually determine metal cation.

2 cl, 2 tbl, 2 ex

FIELD: chemistry.

SUBSTANCE: invention relates to zinc complex of asymmetric ethylenediamine-N,N-dipropyonic acid dichloride of formula Also claimed is method of its obtaining. Complex can be applied for solution of problems, associated with the necessity to introduce Zn2+ in chelate form instead of its mineral salts, as well as to serve as initial product for synthesis of other chemical compounds of series of polydentate ligands, in particular asymmetric ethylenediamine-N,N-dipropyonic acid.

EFFECT: obtaining zinc complex of asymmetric ethylenediamine-N,N-dipropyonic acid dichloride.

4 cl, 4 dwg, 3 ex

FIELD: biotechnologies.

SUBSTANCE: invention refers to a compound having general formula (I),

where: m and n are independent integer numbers of 1 to 6; each of X1-X3 and Y1-Y3 is O; each of R1-R3 is independently chosen from a group consisting of hydrogen or alkyl; and R is O-(CH2)x-C(-O)NR'-(CH2)y-NHR'. Besides, x and y are independent integer numbers of 1 to 6; and R' is chosen from the group consisting of hydrogen and alkyl. In addition, an antibody containing an antigen recognition area, use of the compound, pharmaceutical composition, use of the antibody, method for MMP-2 or MMP-9 activity inhibition in a sample and a composition for determining MMP-2 or MMP-9 are proposed.

EFFECT: invention allows obtaining compounds that are able to inhibit MMP-2 or MMP-9 activity.

11 cl, 16 dwg, 4 tbl, 11 ex

FIELD: chemistry.

SUBSTANCE: invention relates to molecular complexes of zinc and cadmium bis(1-phenyl-3-methyl-4-formyl-5-pyrazolonate) with amino-derivatives of nitric heterocycles of general formula (I) (NH2-Het)n, where NH2-Het is 1-aminoisoquinoline, 3-aminoquinoline, 6-aminoquinoline, 5-amino-4,6-dimethylquinoline, 2-aminopyridine, 2-amino-5-bromopyridine, 3-amino-5-methylisoxazole, 2-amino-1-ethylbenzimidazole, M is Zn, Cd, n=1, 2.

EFFECT: molecular complexes of formula (I) exhibit luminescent properties in the blue region of the spectrum and can be used as phosphors for making organic light-emitting diodes of white and visible light.

14 ex

FIELD: chemistry.

SUBSTANCE: invention relates to electroluminescent substances and specifically to zinc (II) bis{3-methyl-1-phenyl-4-[(quinoline-3-imino)-methyl]1-H-pyrazol-5-onato} of general formula I . Also disclosed is an electroluminescent device which contains zinc (II) bis{3-methyl-1-phenyl-4-[(quinoline-3-imino)-methyl]1-H-pyrazol-5-onato} of general formula I.

EFFECT: compound exhibits electroluminscent properties in the yellow spectral region with high brightness.

2 cl, 4 ex

FIELD: chemistry.

SUBSTANCE: method involves reaction of a zinc halide with trialkylaluminium containing a hydride and trialkylaluminium with one or more polymerised alkyl groups. Content of hydride in trialkylaluminium ranges from 0.01 wt % to 0.10 wt %. After reaction, dialkylzinc containing not more than 10 ppmw aluminium is separated from the reaction products and dialkylaluminium monohalide containing not more than 10 ppmw zinc is then separated.

EFFECT: invention enables to obtain dialkylzinc and dialkylaluminium monohalide of high purity and with high output.

7 cl, 2 dwg, 1 tbl, 5 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel substituted metal phthalocyanines, which can be used as direct and acid dyes for dyeing cotton and protein fibre. Disclosed are tetra-4-[(4'-carboxy)phenylamino]phthalocyanine metal complexes of formula, where M=Cu, Ni, Zn.

EFFECT: metal phthalocyanines expand the colour gamma of the current light-blue copper tetra-4-carboxyphthalocyanine, which is the closest on structure and application, to a blue-green and green colour.

6 dwg, 5 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a method of producing zinc meso-tetra-aminotetrabenzoporphyrinate. The method involves reaction of a phthalic anhydride with aminoacetic acid to obtain N-carboxymethylphthalimide, from which while heating with zinc oxide, a zinc salt of N-carboxymethylphthalimide is obtained. The obtained salt reacts with phthalimide at high temperature from 240°C to 320°C for 2-2.5 hours, followed by treatment of the reaction mass with hydrazine hydrate in pyridine solution at boiling point thereof for 1.5-2 hours.

EFFECT: high safety of the process owing to prevention of formation of dangerous and toxic acetic and nitric acids, high cost-effectiveness of the process and obtaining an end product of high purity.

3 dwg

FIELD: chemistry.

SUBSTANCE: disclosed are novel phthalocyanines, which are quaternised derivates of zinc and aluminium tetra(3-thiophenyl)phthalocyanines of formula MPc(SPh)4Rn, where: MPc(SPh)4Rn is zinc or aluminium tetra(3-thiopheny)phthalocyanine, M=Zn, AlX; X=Cl, HO, , , n=4-9. The disclosed phthalocyanines are sensitising agents for formation of singlet oxygen under the effect of visible light. Also disclosed is a method of treating water using said phthalocyanines or mixture thereof with acridine, rhodamine or phenothiazine dyes and visible light in the presence of oxygen.

EFFECT: efficient treatment of water from bacterial contamination.

2 cl, 1 dwg, 3 tbl, 7 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to new pyrido[2,3-b]pyrazine derivatives of general formula (I), wherein radicals and symbols are specified in the patent claim. The given compounds inhibit the enzymes ERK, ERK1, ERK2, PI3K, PI3Kalpha, PI3Kbeta, PI3Kgamma, PI3Kdelta, PI3K-C2alpha, PI3K-C2beta, PI3K-Vps34p.

EFFECT: invention refers to a pharmaceutical composition to be used for preparing the drugs applicable first for treating malignant and other diseases implying the pathological cell proliferation.

10 cl, 3 tbl, 66 ex

Up!